NCT01396135 - A Phase 1 Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects | Biotech Hunter

Timeline

Start Date

August 26, 2011

Primary Completion Date

October 29, 2011

Study Completion Date

October 29, 2011

Conditions

Healthy

Interventions

DRUG

CP-601,927

Single dose of 1 mg CP-601,927 given as oral 1 mg tablets

DRUG

CP-601,927

Single dose of 2 mg CP-601,927 given as oral 1 mg tablets

DRUG

CP-601,927

Single dose of 3 mg CP-601,927 given as oral 1 mg tablets

DRUG

Placebo

Single dose of placebo given as a matching number of oral tablets

DRUG

CP-601,927

Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days

DRUG

Placebo

Multiple doses of placebo given as a matching number of oral tablets